105 related articles for article (PubMed ID: 8704709)
1. Long-term remission obtained by intensive chemotherapy against a leukemic relapse and subsequent graft-versus-host disease following an allogeneic BMT in a patient with myelodysplastic syndrome.
Azuno Y; Kamei S; Kaku K; Yoshida T; Oeda E; Nishimura M; Okafuji K; Takeuchi Y; Tanaka M; Oka Y; Hiroshige Y; Kaneko T
Bone Marrow Transplant; 1996 Mar; 17(3):463-4. PubMed ID: 8704709
[No Abstract] [Full Text] [Related]
2. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host reaction affecting lesional skin but not normal skin in a patient with piebaldism.
Chow RK; Stewart WD; Ho VC
Br J Dermatol; 1996 Jan; 134(1):134-7. PubMed ID: 8745900
[TBL] [Abstract][Full Text] [Related]
4. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
[TBL] [Abstract][Full Text] [Related]
6. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7.
Skinner R; Velangi M; Bown N
Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642
[TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
Azuno Y; Kaneko T; Nishimura M; Okuya S; Nakai K; Nomiyama J; Mori K; Okafuji K; Okubo M; Matsutani A; Kamei S; Zaitsu Y; Takeuchi Y; Oka Y; Kaku K
Bone Marrow Transplant; 1996 Jul; 18(1):257-9. PubMed ID: 8832032
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
10. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
11. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
13. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation.
Spinelli S; Chiodi S; Costantini S; Van Lint MT; Raiola AM; Ravera GB; Bacigalupo A
Haematologica; 2003 Oct; 88(10):1163-8. PubMed ID: 14555313
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
Toze CL; Galal A; Barnett MJ; Shepherd JD; Conneally EA; Hogge DE; Nantel SH; Nevill TJ; Sutherland HJ; Connors JM; Voss NJ; Kiss TL; Messner HA; Lavoie JC; Forrest DL; Song KW; Smith CA; Lipton J
Bone Marrow Transplant; 2005 Nov; 36(9):825-30. PubMed ID: 16151430
[TBL] [Abstract][Full Text] [Related]
16. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
17. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
18. Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation?
Burger J; Gmür J; Bruckner-Tuderman L
Bone Marrow Transplant; 1992 Feb; 9(2):139-41. PubMed ID: 1571712
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Rondón G; Giralt S; Huh Y; Khouri I; Andersson B; Andreeff M; Champlin R
Bone Marrow Transplant; 1996 Sep; 18(3):669-72. PubMed ID: 8879640
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-host disease: effects on long term disease free survival in marrow transplantation for haematological malignancies.
Kapoor N; Copelan EA; Klein J; Tutschka PJ
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():153-5. PubMed ID: 2697430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
